Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi.
Saved in:
| Title: | Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi. |
|---|---|
| Authors: | Robertson SJ; Department of Dermatology, The Royal Children's Hospital, The Royal Melbourne Hospital and Monash Medical Centre, Melbourne, Australia.; Murdoch Children's Research Institute, Melbourne, Australia., Orme L; Department of Oncology, The Royal Children's Hospital, Melbourne, Australia.; Peter MacCallum Cancer Centre, Melbourne, Australia., Teixeira R; Department of Plastic Surgery, The Royal Children's Hospital, Melbourne, Australia.; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia., Shamassi M; Department of Anatomical Pathology, The Royal Children's Hospital, Melbourne, Australia., Newell F; Department of Genetics and Computational Biology, QIMR (Queensland Institute of Medical Research) Berghofer Medical Research Institute, Brisbane, Australia., Patch AM; Department of Genetics and Computational Biology, QIMR (Queensland Institute of Medical Research) Berghofer Medical Research Institute, Brisbane, Australia., Yeh I; Helen Diller Family Comprehensive Cancer Center, Departments of Dermatology and Pathology, University of California, San Francisco., Gard G; Department of Medical Oncology, Alfred Health, Melbourne, Australia., Wilmott J; Melanoma Institute Australia, University of Sydney, Sydney, Australia., Jackett L; Melanoma Institute Australia, University of Sydney, Sydney, Australia.; Sydney Medical School, University of Sydney, Sydney, Australia.; Royal Prince Alfred Hospital, Camperdown, Australia., LeBoit P; Helen Diller Family Comprehensive Cancer Center, Departments of Dermatology and Pathology, University of California, San Francisco., Fellowes A; Peter MacCallum Cancer Centre, Melbourne, Australia., MacArthur G; Peter MacCallum Cancer Centre, Melbourne, Australia., Fox S; Peter MacCallum Cancer Centre, Melbourne, Australia., Hayward NK; Department of Genetics and Computational Biology, QIMR (Queensland Institute of Medical Research) Berghofer Medical Research Institute, Brisbane, Australia., Bastian B; Helen Diller Family Comprehensive Cancer Center, Departments of Dermatology and Pathology, University of California, San Francisco., Scolyer R; Melanoma Institute Australia, University of Sydney, Sydney, Australia.; Sydney Medical School, University of Sydney, Sydney, Australia.; Royal Prince Alfred Hospital, Camperdown, Australia., Waddell N; Department of Genetics and Computational Biology, QIMR (Queensland Institute of Medical Research) Berghofer Medical Research Institute, Brisbane, Australia., Penington A; Murdoch Children's Research Institute, Melbourne, Australia.; Department of Plastic Surgery, The Royal Children's Hospital, Melbourne, Australia.; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia., Shackleton M; Peter MacCallum Cancer Centre, Melbourne, Australia.; Department of Medical Oncology, Alfred Health, Melbourne, Australia.; Central Clinical School, Monash University, Melbourne, Australia. |
| Source: | JAMA dermatology [JAMA Dermatol] 2021 Jul 01; Vol. 157 (7), pp. 836-841. |
| Publication Type: | Case Reports; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589530 Publication Model: Print Cited Medium: Internet ISSN: 2168-6084 (Electronic) Linking ISSN: 21686068 NLM ISO Abbreviation: JAMA Dermatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2168-6084 |
|---|---|
| DOI: | 10.1001/jamadermatol.2021.0025 |
